FDA Approvals Roundup: Qelbree, Sarclisa, Tyvaso
FDA Approvals Roundup: Qelbree, Sarclisa, Tyvaso Posted 07 April 2021 | By Renee Matthews A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). New approvalsQelbree okayed as nonstimulant therapy option for children with ADHDSupernus’s Qelbree (viloxazine extended-release capsules) has been approved for the treatment of attention deficit hyperactivity […]
Read More